pharma industry analysis

57
K J Somaiya Institute of Management studies & research 2012 OVERVIEW of PHARMACEUTICAL INDUSTRY Submitted by Nitin Palve Dibyajyoti Bose Rangoli Singh

Upload: nitin-palve

Post on 08-Aug-2015

201 views

Category:

Documents


2 download

DESCRIPTION

Pharma Industry

TRANSCRIPT

Page 1: Pharma industry analysis

K J Somaiya Institute of Management studies & research

2012

OVERVIEW of

PHARMACEUTICAL

INDUSTRY Submitted by

Nitin Palve Dibyajyoti Bose Rangoli Singh

Page 2: Pharma industry analysis

ACKNOWLEDGEMENT

We place on record and warmly acknowledge the continuous encouragement, invaluable supervision, timely suggestions and inspired guidance offered by our guide Dr. J S Lamba , K J Somaiya Institute of Management Studies and Research ,Mumbai, in bringing this report to a successful completion. We are grateful to Dr. J S Lamba for permitting us to make use of the facilities available in the department to carry out the project successfully. Apart, he has been helping closely at a personal level and we acknowledge his contribution. Last but not the least we express our sincere thanks to all of our friends who have patiently extended all sorts of help for accomplishing this undertaking. Finally we extend our gratefulness to one and all who are directly or indirectly involved in the successful completion of this project work .

Nitin Palve Dibyajyoti Bose

Rangoli Singh

Page 3: Pharma industry analysis

DECLARATION

We hereby declare that the project work entitled “Overview of Pharmaceutical Industry” submitted to the K J Somaiya Institute of Management Studies and Research ,Mumbai, is a record of an original work done by us under the guidance of Dr. J S Lamba This project work is submitted in the partial fulfillment of the requirements for the Operations Management subject for PGDM Programme. The results embodied in this course have not been submitted to any other University or Institute for the award of any course. Date- 02-Oct-2012 Place-SIMSR,

Mumbai

Nitin Palve

Dibyajyoti Bose Rangoli Singh

Page 4: Pharma industry analysis

CERTIFICATE

This is to certify that the Project entitled, ” Overview of Pharmaceutical Industry ” submitted by Nitin Palve, Dibyajyoti Bose, Rangoli Singh in partial fulfillments for the requirements for course of Operations management at K J Somaiya Institute of Management Studies and Research, Mumbai An authentic work carried out by Nitin Palve, Dibyajyoti Bose, Rangoli Singh under my supervision and guidance. To the best of my knowledge, the matter embodied in the Project has not been submitted to any other University / Institute for any course.

Date:

Dr. J S Lamba K J Somaiya Institute of Management Studies and Research, Mumbai

Page 5: Pharma industry analysis

Contents

1 Pharmaceutical Industry Overview .................................................................................................. 7

1.1 Pharmaceutical Industry ............................................................................................................... 7

1.2 Global Scenario ............................................................................................................................. 7

1.3 Indian pharmaceutical Industry .................................................................................................. 10

1.3.1 Overview ............................................................................................................................. 10

1.3.2 Exports ................................................................................................................................ 12

2 Marketing strategies ......................................................................................................................... 13

2.1 Market characteristics’ ............................................................................................................... 13

2.2 Marketing Process in Pharmaceutical Industry .......................................................................... 14

2.2.1 Strategies for External customers ....................................................................................... 15

2.2.2 Strategies for the Internal Customers ................................................................................. 17

2.3 Market Demand & Product share ............................................................................................... 17

3 Manufacturing Process & Operations ............................................................................................. 18

3.1 Introduction ................................................................................................................................ 18

3.2 R&D ............................................................................................................................................. 19

3.3 Tablet manufacturing Process .................................................................................................... 20

3.3.1 Dispensing (weighing and measuring) ................................................................................ 20

3.3.2 Granulation : ....................................................................................................................... 21

3.3.3 Sizing ................................................................................................................................... 21

3.3.4 Powder blending ................................................................................................................. 22

3.3.5 Drying .................................................................................................................................. 23

3.3.6 Tablet compression ............................................................................................................. 23

3.3.7 Tablet Coating ..................................................................................................................... 24

3.3.8 Packaging ............................................................................................................................ 25

3.4 Capsule manufacturing ............................................................................................................... 25

3.5 Liquid ........................................................................................................................................... 25

3.5.1 Liquids for oral administration ............................................................................................ 25

3.5.2 Liquids for intraveneous administration ............................................................................. 25

3.5.3 Liquids for topical application ............................................................................................. 26

Page 6: Pharma industry analysis

3.6 GOOD MANUFACTURING PRACTICE ........................................................................................... 26

3.7 THE ROLE OF THE LABORATORY ................................................................................................. 27

3.8 Manufacturing: Cost drivers ....................................................................................................... 28

3.8.1 Elements of cost .................................................................................................................. 28

4 Pharmaceutical Supply chain .............................................................................................................. 31

4.1 Pharmaceutical Value chain / Supply chain ............................................................................... 31

4.1.1 Pharmacy Supply Chain Considerations .............................................................................. 31

4.2 Supply chain factors .................................................................................................................... 32

4.2.1 Source - Suppliers................................................................................................................ 32

4.2.2 Make ................................................................................................................................... 34

4.2.3 Distribute ............................................................................................................................ 36

4.2.4 Buy – retailers ..................................................................................................................... 38

4.3 Supply chain ................................................................................................................................ 38

4.3.1 Operational issues in the pharmaceutical supply chain ..................................................... 39

4.4 Supply chain: Future ................................................................................................................... 42

4.4.1 Removing the roadblocks.................................................................................................... 43

5 Top Growth Drivers of Pharmaceutical Industry ................................................................................ 46

6 Challenges for Pharmaceutical Industry ............................................................................................. 50

6.1 Changing trends & Implications .................................................................................................. 50

6.2 Manufacturing challenges ........................................................................................................... 51

6.3 Supply chain challenges .............................................................................................................. 52

6.4 Other Challenges for Pharmaceutical industry in India .............................................................. 53

7 References .......................................................................................................................................... 54

Page 7: Pharma industry analysis

1 Pharmaceutical Industry Overview

1.1 Pharmaceutical Industry

The pharmaceutical industry can be defined as a complex of processes, operations and organizations involved in the discovery, development and manufacture of drugs and medications. The World Health Organization (WHO) defines a drug or pharmaceutical preparation as: any substance or mixture of substances manufactured, sold, offered for sale or represented for use in the diagnosis, treatment, mitigation or prevention of disease, abnormal physical state or the symptoms thereof in man or animal; [and for use in] restoring, correcting or modifying organic functions in man or animal. This is a very wide definition, and correspondingly, there are number of key players in the pharmaceutical industry, including:

• The large, research and development-based multinationals with a global presence in branded products, both ethical/prescription and over-the-counter. They tend to have manufacturing sites in many locations.

• The large generic manufacturers, who produce out-of-patent ethical products and over-the-counter products.

• Local manufacturing companies that operate in their home country, producing both generic products and branded products under licence or contract.

• Contract manufacturers, who do not have their own product portfolio, but produce either key intermediates, active ingredients (AI) or even final products by providing outsourcing services to other companies,.

• Drug discovery and biotechnology companies, often relatively new start-ups with no significant manufacturing capacity.

1.2 Global Scenario

Page 8: Pharma industry analysis
Page 9: Pharma industry analysis

Market leader by market capitalization (billion $)

Page 10: Pharma industry analysis

1.3 Indian pharmaceutical Industry

1.3.1 Overview

Background

• Drugs industry in India dates back to the year 1901 • Growth phase since 1950s - Advent of multinationals • Bulk drugs - (raw material) inputs for drug formulations • Around 465 bulk drugs used; of these, 425 are manufactured locally

Regulations

• Drugs and Cosmetics Act, 1940; Rules 1945 – controls and licenses the manufacture, packing, selling and distribution of drugs and formulations

• National Pharmaceutical Pricing Authority, 1997 - decides on prices of formulations - implemented through Drug Price Control Order (DPCO)

• Licensing abolished in 1994 - foreign equity allowed upto 51 % • At the moment, only process patenting & product patents of drugs allowed; no product

patents are allowed before 1995

Industry Structure

• Over 350 units into bulk drugs production in the organised sector • Several more in the unorganised sector • Around 300 units, in paracetamol production alone, mostly for exports • In house bulk drug production units or sub contractors for large pharmaceutical

companies • Bulk drugs units concentrated largely around Hyderabad

Technology

• Basic chemicals and intermediary chemicals / enzymes for bulk drug manufacture sourced indigenously

• Raw materials constitute 70% of total cost of production • Process technology for drugs obtained through reverse engineering mode • (Absence of product patent laws has facilitated this mode) • Usually, cheaper chemical synthesis process or at times, fermentation processes

employed • For select drugs, technology tie-ups with foreign partners also being done.

India currently represents just U.S. $6 billion of the $550 billion global pharmaceutical

industry but its share is increasing at 10 percent a year, compared to 7 percent annual

growth for the world market overall.

Also, while the Indian sector represents just 8 percent of the global industry total by

volume, putting it in fourth place worldwide, it accounts for 13 percent by value, and its

drug exports have been growing 30 percent annually. The “organized” sector of India's

Page 11: Pharma industry analysis

pharmaceutical industry consists of 250 to 300 companies, which account for 70 percent

of products on the market, with the top 10 firms representing 30 percent. However, the

total sector is estimated at nearly 20,000 businesses, some of which are extremely small.

Approximately 75 percent of India's demand for medicines is met by local manufacturing.

According to the German Chemicals Association, in 2005, India's top 10 pharmaceutical

companies were Ranbaxy, Cipla, Dr. Reddy's Laboratories, Lupin, Nicolas Piramal,

Aurobindo Pharma, Cadila Pharmaceuticals, Sun Pharma, Wockhardt Ltd. and Aventis

Pharma.

Indian-owned firms currently account for 70 percent of the domestic market, up from less

than 20 percent in 1970. In 2005, nine of the top 10 companies in India were

domestically owned, compared with just four in 1994. India's potential to further boost its

already-leading role in global generics production, as well as an offshore location of

choice for multinational drug manufacturers seeking to curb the increasing costs of their

manufacturing, R&D and other support services, presents an opportunity worth an

estimated $48 billion.

Some of leading Indian players are shown in table below

Company Name

Market Cap

(Rs. cr)

Sun Pharma 69,622.17

Cipla 29,294.59

Dr Reddys Labs 28,469.27

Lupin 25,381.65

Ranbaxy Labs 22,232.25

Cadila Health 17,171.23

GlaxoSmithKline 16,939.33

Divis Labs 14,493.92

Wockhardt 13,562.94

Glenmark 11,153.88

Piramal Health 8,111.33

Torrent Pharma 5,693.08

Page 12: Pharma industry analysis

1.3.2 Exports

Over 60 per cent of India’s bulk drug production is exported. India’s pharmaceutical

exports are to the tune of Rs87 billion, of which formulations contribute nearly 55 per

cent and the rest 45 per cent comes from bulk drugs. In financial year 2005, exports

grew by 21 per cent. The Indian pharmaceutical market has been forecasted to grow

to as much as US$ 25 billion by 2010 as per Organization of Pharmaceutical Producers

of India (OPPI) estimates. However, Espicom’s market projections forecast more

modest but stable annual market growth of around 7.2 per cent, putting the market at

US$ 11.6 billion by 2009.

Revenue from Export

India accounts for less than two per cent of the world market for pharmaceuticals, with

an estimated market value of US$10.4 billion in 2007 at consumer prices, or around

US$9 per capita.

India currently represents just U.S. $6 billion of the $550 billion global pharmaceutical

industry but its share is increasing at 10 percent a year, compared to 7 percent annual

growth for the world market overall. Also, while the Indian sector represents just 8

percent of the global industry total by volume, putting it in fourth place worldwide, it

accounts for 13 percent by value, and its drug exports have been growing 30 percent

annually. Cipla, Nicholas Piramal, Ranbaxy, Zydus Cadila, Dr. Reddy’s are the few Indian

pharmaceutical companies, which are known at the global level due to their quality

products.

Page 13: Pharma industry analysis

2 Marketing strategies

2.1 Market characteristics’

Pricing

• Drug Prices Control Order (DPCO) 1970,

- fixes & monitors prices in tandem with the Drug Policy - specific drugs (76) controlled under public interest - this specified list is coming down now

• Prices fixed after considering costs; binding on all units in that category (inclusive of imports for resale purpose)

• However, market competition may force prices below DPCO levels,

Market Characteristics

• Bulk drugs - a commoditised market in India • Availability of drugs in India - good; and at affordable prices (DCPO is one

reason) • Patent laws not being (applicable) enforced; so, most globally patented drugs

are available at lower prices • Original drugs developed include Peruvoside (Cardiatonic), Centimizone (anti-

thyroid), Gugulipid, (Hypolipidemic) • Drugs prices amongst cheapest globally • Stiff competition - so, patent holders source drugs from cheaper local

manufacturers • Direct supplies of bulk drugs to formulation units • Stringent quality norms - especially for exporting units

Page 14: Pharma industry analysis

Demand Drivers

2.2 Marketing Process in Pharmaceutical Industry

Marketing is based around providing continual benefit to the customers, these benefits

will be provided and a transactional exchange will take place.

Effective Marketing process and planning in Pharma Industry include:

� Marketing Aspects of the Disease

� Product Background

� Target market

� Competitive Environment

� SWOT Analysis

� Commercial Goals and Financial Forecast

� Budget: Planned marketing and Sales investment

� Positioning/Product Story/Unique Selling Proposition

� Branding Guidelines

� Target groups

� Internal Communication Program

� External Communication

� Packaging

� Pricing Strategy

� Market Access and Health Economic Outcomes Research

� Co-operations, Licensing and Strategic Alliances

Page 15: Pharma industry analysis

Marketing strategies are planned by targeting the 4 different external customers as well the internal customers.

External customers are:

� Patients: Patients are the customers, who are considered before planning a product segment

� Physicians: Who are targeted for getting prescriptions? � Chemists: Who are targeted for availability & sales of products on

prescriptions of physicians? � Wholesalers: Who are targeted for primary sales & availability of

products for chemists? Internal customers are the team of Medical Representatives & Sales Managers-

� Who work in coordination with each other � As per the norms laid by company � Implementing strategies & � Utilization of inputs provided by company achieves the sales targets given to

them.

2.2.1 Strategies for External customers

2.2.1.1 Strategies for Prescribing Physicians

o Physicians are the target customers for the company; hence the company is

always trying to develop the strategy so that there is increase in the physicians. o The strategy developed for the doctors mainly includes: o Selection of the customers through conduction of detailed survey. o Validating the potential of each potential & finalization of list of physicians. o Positioning of the products depending upon the prescribing habits of the

physicians. o Detailing of the products to the physicians & providing free drug samples. o Regular follow-ups with the physicians & chemists for continuity of prescriptions

flow & availability. o Providing the informative literatures for updating the current developments in

the medicines. o Organizing Health check-up camps for the physicians & patients. o Categorizing Doctor according to the prescription support & planning promotional

materials. o Giving gifts as token for gesture & sponsorships to the physicians

2.2.1.2 Strategies for Patients

Main policy for patient’s benefit is cost economy. Indian population is mix of income

level but dominated by poor patients, who lives in slums & villages, whose purchasing

Page 16: Pharma industry analysis

capacity is already low & who cannot afford to purchase medicines for their day to day

illness. Company need to focus these customers as well while deciding for pricing

strategies, due to cost economy, these customers become able to purchase complete

therapy & treatment

2.2.1.3 Strategies for Retail Chemists

Chemists are the peoples, who are having their retails shops near the physician’s

clinics/hospitals. A patient carries the prescription to the retail chemists, who then

dispenses the medicines, prescribed by the physicians. Hence retails chemists are also

considered to be another most important customer to be targeted by the company.

Hence Company has to develop separate strategy keeping in core the chemist.

� Giving discount on purchase to the retail chemists.

� Giving additional bonus offers on purchase of products

� Giving gifts on purchase. Like in Monsoon season, on purchase of a volume, the

retails chemists will get umbrella, raincoat or other products or Kitchen utensils

or coupon for lucky draw.

� Facility of expiry products reimbursement. The expiry will be settled immediately

in next purchase invoice made by the retail chemists; hence no dues will remain

pending for long time.

2.2.1.4 Strategies for Distributors and wholesalers

This is another level in the channel of distribution, if ignored or not handled properly,

may not result in profitable businesses in the respective market. Wholesalers are the

bulk purchasers, who call upon the products from company for distribution in the market

& ensure availability of the products to be dispensed on doctor’s prescription. Since

wholesalers are directly paying to the company against whatever products they

purchases, must be carefully managed. Wholesalers invests huge amount in their

business, purchases on net from companies & sales to retailers on credit for a period

ranging from 1 month to whatever period is decided by the wholesaler depending upon

the credibility of the retailers. Since these wholesalers get their money back from the

retailers after a long time, they want some benefits from the companies for their net &

bulk purchases as some return on investments.

� Company, as knowing this need to provide better return on investments to

wholesalers by-

� Providing bonus offers on bulk purchases

� Providing cash discounts on repayments before the credit terms.

� Providing gifts & incentives for various purchase amounts.

� Various offers to the retailers in terms of gifts, vouchers on volume purchases,

hence liquidation of stocks from the wholesalers in short times

Page 17: Pharma industry analysis

2.2.2 Strategies for the Internal Customers

Medical Representatives (MR’s), First Line Sales Manager (ASM’s) & Second Line Sales Manager are the internal customers who are actually involved in strategic implementation & achieving sales targets through prescription generation from the physicians. MR’s are required to prepare a list of doctors of doctors, depending upon their volume of business they have to categorize

• Selecting the MR’s irrespective of their qualifications & prior experience • Though initially salary given was less (As company’s sales base & profitability

was less), company need to take a strategic decision of giving additional performance based incentives to their MR’s. This motivated people to increase the sales month after month, with the help of support of inputs given by the company.

• There were product wise sales incentives also available. On sales of a particular product, MR will get a specific amount of incentives.

• Flexibility in Tour Program (TP) was given to MR’s as well ASM’s, depending upon need & potential of market as well customer, they can move other towns, areas to cover VIP doctors, if missed due to some unavoidable reasons, so that business can be ensured.

• The trust & homely environment is provided to MR’s, which encouraged them to work for a home company like a family business.

2.3 Market Demand & Product share

The industry has enormous growth potential. Factors listed below determine the rising

demand for pharmaceuticals.

• The growing population of over of a billion

• Increasing income

• Demand for quality healthcare service

• Changing lifestyle has led to change in disease patterns, and increased

demand for

• new medicines to combat lifestyle related diseases

More than 85 per cent of the formulations produced in the country are sold in the

domestic market. India is largely self-sufficient in case of formulations. Some life

saving, new generation under-patent formulations continue to be imported, especially

by MNCs, which then market them in India. Overall, the size of the domestic

formulations market is around Rs160 billion and it is growing at 10 per cent per annum.

Page 18: Pharma industry analysis

Market share of different pharmaceutical product categories

3 Manufacturing Process & Operations

3.1 Introduction

The pharmaceutical industry takes the active ingredients of drugs (which are may be imported from overseas) and converts them into a form that can easily be given to a patient. This involves mixing the active ingredient with various other ingredients with appropriate chemical properties, then either compressing the mixture into a tablet, filling a gelatin capsule with it or dissolving it in an appropriate solvent.

Page 19: Pharma industry analysis

3.2 R&D

R & D - Strategies R & D - Indian Corporates

• Indian industry moving from reverse engineering of drugs to R&D, after signing of WTO (TRIPS)

• Around US $ 300 million has to be spent over a 10 - 15 year span, involving extensive analyses, global test marketing etc

• Larger Indian firms have diverted more resources

- to chemical synthesis of basic molecules for domestic & international markets (Dr Reddy’s Lab, Ranbaxy Laboratories) - to further value additions through novel drug delivery systems (Cipla, Wockhardt, Sun Pharma, Ranbaxy Laboratories)

• Some Indian companies have entered into contract testing - where foreign partners could test, post molecule identification stage.

• For some others, drug discovery research is done till development stage; clinical trials are then licensed out to international majors (A global trend

- even European / Japanese companies use this route)

• Collaborations in R&D with foreign research-based firms ( Ranbaxy & Eli Lilly)

• Ranbaxy - has invested over Rs. 300 crores (US $ 70 million) in R &D over the last 3 years (3.45 % of net sales)

• Focus on development of new drugs in the area of anti-infective, respiratory and cardiovascular

• For new drug deliver systems, Ranbaxy has an alliance with Bayer, Germany for licensing the technology for ciprofloxacin (it is successful in applying new delivery systems on cephelexin, ciprofloxacin, etc.)

• Dr. Reddy’s has invested 3% of its net sales in R&D

• Company focuses on new discoveries in diabetes, cancer, acid peptides and bacterial infections

• They have 20 patents for antidiabetic compounds & 22 patents for anti cancer compounds in USA;Dr. Reddy’s Foundations has been granted 3 patents so far - 2 of its compounds are into clinical trials with Novo Nordisk

Page 20: Pharma industry analysis

3.3 Tablet manufacturing Process

The manufacture of oral solid dosage forms such as tablets is a complex multi-stage

process under which the starting materials change their physical characteristics a

number of times before the final dosage form is produced.

Various Unit Operation Sequences in Tablet Manufacturing

Numerous unit processes are involved in making tablets, including particle size reduction

and sizing, blending, granulation, drying, compression, and (frequently) coating. Various

factors associated with these processes can seriously affect content uniformity,

bioavailability, or stability.

3.3.1 Dispensing (weighing and measuring)

Dispensing is the first step in any pharmaceutical manufacturing process. Dispensing is

one of the most critical steps in pharmaceutical manufacturing; as during this step, the

weight of each ingredient in the mixture is determined according to dose.

Dispensing may be done by purely manual by hand scooping from primary containers

and weighing each ingredient by hand on a weigh scale, manual weighing with material

lifting assistance like Vacuum

transfer and Bag lifters, manual or assisted transfer with automated weighing on weigh

table, manual or assisted filling of loss-in weight dispensing system, automated

dispensaries with mechanical devices such as vacuum loading system and screw feed

system.

Issues like weighing accuracy, dust control (laminar air flow booths, glove boxes),

during manual handling, lot control of each ingredient, material movement into and out

of dispensary should be considered during dispensing.

Page 21: Pharma industry analysis

Typical Manufacturing Process of Tablet

3.3.2 Granulation :

This is the stage in which the tablet ingredients are thoroughly mixed, and prepared for compressing. Traditionally, tablets have been made by granulation, a process that imparts two primary requisites to formulate : compactibility and fluidity. Both wet granulation and dry granulation (slugging and roll compaction) are used. Regardless of whether tablets are made by direct compression or granulation, the first step, milling and mixing, is the same; subsequent step differ.

3.3.3 Sizing

The sizing (size reduction, milling, crushing, grinding, pulverization) is an impotent step

(unit operation) involved in the tablet manufacturing.

In manufacturing of compressed tablet, the mixing or blending of several solid

ingredients of pharmaceuticals is easier and more uniform if the ingredients are

approximately of same size. This provides a greater uniformity of dose. A fine particle

size is essential in case of lubricant mixing with granules for its proper function.

Page 22: Pharma industry analysis

Advantages associated with size reduction in tablet manufacture are as follows:

• It increases surface area, which may enhance an active ingredient’s dissolution

rate and hence bioavailability.

• Improved the tablet-to-tablet content uniformity by virtue of the increased number

of

particles per unit weight.

• Controlled particle size distribution of dry granulation or mix to promote better flow

of

mixture in tablet machine.

• Improved flow properties of raw materials.

• Improved colour and/or active ingredient dispersion in tablet excipients.

• Uniformly sized wet granulation to promote uniform drying.

There are also certain disadvantages associated with this unit operation if not controlled

properly. They are as follows:

• A possible change in polymorphic form of the active ingredient, rendering it less

or totally inactive, or unstable.

• A decrease in bulk density of active compound and/or excipients, which may cause

flow problem and segregation in the mix.

• An increase in surface area from size reduction may promote the adsorption of air,

which may inhibit wettability of the drug to the extent that it becomes the limiting

factor in dissolution rate.

A number of different types of machine may be used for the dry sizing or milling process

depending on whether gentle screening or particle milling is needed. The ranges of

equipment employed for this process includes Fluid energy mill, Colloidal mill, Ball mill,

Hammer mill, Cutting mill, Roller mill, Conical mill, etc.

3.3.4 Powder blending

The successful mixing of powder is acknowledged to be more difficult unit operation

because, unlike the situation with liquid, perfect homogeneity is practically unattainable.

In practice, problems also arise because of the inherent cohesiveness and resistance to

movement between the individual particles. The process is further complicated in many

system, by the presence of substantial segregation influencing the powder mix. They

arise because of difference in size, shape, and density of the component particles.

The powder/granules blending are involved at stage of pre granulation and/or post

granulation stage of tablet manufacturing. Each process of mixing has optimum mixing

time and so prolonged mixing may result in an undesired product. So, the optimum

mixing time and mixing speed are to be evaluated. Blending step prior to compression is

Page 23: Pharma industry analysis

normally achieved in a simple tumble blender. The Blender may be a fixed blender into

which the powders are charged, blended and discharged. It is now common to use a

bin blender which blends.

In special cases of mixing a lubricant, over mixing should be particularly monitored. The

various blenders used include “V” blender, Oblicone blender, Container blender,

Tumbling blender, Agitated powder blender, etc.

But now a days to optimize the manufacturing process particularly in wet granulation

the various improved equipments which combines several of processing steps (mixing,

granulation and/or drying) are used. They are “Mixer granulator” or “High shear mixing

machine”.

3.3.5 Drying

Drying is a most important step in the formulation and development of pharmaceutical

product. It is important to keep the residual moisture low enough to prevent product

deterioration and ensure free flowing properties.

The commonly used dryer includes Fluidized – bed dryer, Vacuum tray dryer, Microwave

dryer, Spray dryer, Freeze dryer, Turbo – tray dryer, Pan dryer, etc.

3.3.6 Tablet compression

After the preparation of granules (in case of wet granulation) or sized slugs (in case of

dry granulation) or mixing of ingredients (in case of direct compression), they are

compressed to get final product. The compression is done either by single punch

machine (stamping press) or by multi station machine (rotary press).

Each tablet is made by pressing the granules inside a die, made up of hardened steel.

The die is a disc shape with a hole cut through its centre. The powder is compressed in

the centre of the die by two hardened steel punches that fit into the top and bottom of

the die.

The punches and dies are fixed to a turret that spins round. As it spins, the punches are

driven together by two fixed cams - an upper cam and lower cam. The top of the upper

punch (the punch head) sits on the upper cam edge .The bottom of the lower punch sits

on the lower cam edge.

The shapes of the two cams determine the sequence of movements of the two punches.

This sequence is repeated over and over because the turret is spinning round.

The force exerted on the ingredients in the dies is very carefully controlled. This ensures

that each tablet is perfectly formed. Because of the high speeds, they need very

sophisticated lubrication systems. The lubricating oil is recycled and filtered to ensure a

continuous supply.

Page 24: Pharma industry analysis

Common stages occurring during compression

Stage 1 : Top punch is withdrawn from the die by the upper cam Bottom punch is low in

the die so powder falls in through the hole and fills the die

Stage 2 : Bottom punch moves up to adjust the powder weight-it raises and expel some

powder

Stage 3 : Top punch is driven into the die by upper cam Bottom punch is raised by lower

cam Both punch heads pass between heavy rollers to compress the powder

Stage 4 : Top punch is withdraw by the upper cam Lower punch is pushed up and

expels the tablet Tablet is removed from the die surface by surface plate

Stage 5 : Return to stage 1

Stage Occurring During Compression

3.3.7 Tablet Coating

Tablets may be coated to improve the stability (by protecting the tablet from exposure to light, moisture or air) and appearance, to mask an unpleasant taste, or to protect the tablet from the acid in the stomach. In addition, outside coatings are sometimes coloured, either to improve their appearance, or to enable them to be easily identified. The majority of coated tablets nowadays use film coating. The solution is sprayed onto the tablets as they are turned in a large rotating bowl, the solvent evaporates off, and a layer of film remains on each tablet. As well as being simpler to apply than sugar coatings, film coatings have the advantage that they can be applied to embossed tablets without the embossing being filled up with coating solution.

Page 25: Pharma industry analysis

3.3.8 Packaging

Pharmaceutical manufacturers have to pack their medicines before they can be sent

out for distribution. The type of packaging will depend on the formulation of the

medicine.

'Blister packs' are a common form of packaging used for a wide variety of products.

They are safe and easy to use and they allow the consumer to see the contents without

opening the pack. Many pharmaceutical companies use a standard size of blister pack.

This saves the cost of different tools and to change the production machinery between

products. Sometimes the pack may be perforated so that individual tablets can be

detached. This means that the expiry date and the name of the product have to be

printed on each part of the package. The blister pack itself must remain absolutely flat

as it travels through the packaging processes, especially when it is inserted into a

carton. This poses interesting problems for the designers. Extra ribs are added to the

blister pack to improve its stiffness.

3.4 Capsule manufacturing

Manufacture of capsules involves a similar process to that of tablets. The major difference is that after mixing of the formulation ingredients, instead of being compressed, the mixture is filled into gelatin capsules that may be either hard or soft in texture.

3.5 Liquid

These fall into three main categories: liquids for oral administration, liquids for injections and liquids applied topically (i.e. creams and ointments).

3.5.1 Liquids for oral administration

These are usually the simplest formulations available, as the ingredients are simply mixed in a suitably sized tank. The most important aspect of manufacture is to ensure all ingredients are fully dissolved and well mixed before packing and that the formulations contain suitable effective preservatives. Where the liquid is a suspension, mixing of the bulk must be continued during packing to ensure even dispersion of the active at all times. These liquids generally include, in addition to the active ingredient and the solvent (usually water, although alcohol sometimes used as a solvent or cosolvent2), antimicrobial agents to prevent the growth of molds and yeasts, and often include sweeteners such as sucrose, sorbitol, aspartame and glycerin. In addition, a variety of other substances are sometimes used to alter such properties as solubility, flavour and viscosity.

3.5.2 Liquids for intraveneous administration

Liquids for injections are also usually simple to prepare, however, manufacture must occur under aseptic conditions using methods that ensure the finished injection is sterile. Injections are usually rendered sterile by autoclaving3; however, some medicines cannot be autoclaved and so must be sterilised by filtration during the manufacturing process.

Page 26: Pharma industry analysis

As well as being available in liquid form, injections may, for stability purposes, be prepared in powder form, either freeze dried or as pure powder, for reconstitution immediately prior to use. Injections may also be prepared for intramuscular or subcutaneous administration often using oils as the vehicle rather than water. Injected liquids sometimes also contain small amounts of additives, the most common of these being sodium chloride (table salt) - used in aqueous solutions to make the injected solution isotonic

3.5.3 Liquids for topical application

Liquids for topical application are usually prepared as either ointments or creams. The general difference between these forms is that ointments in the majority of cases are dispersions of water in oils while creams are the opposite. The method of manufacture is, however, the same. It involves preparation of separate oil and water phases containing the required ingredients, heating each phase to between 60-70°C, mixing and then cooling the mixture with stirring until the cream or ointment is formed. The bases used are substances such as hydrocarbons and lanolin. Depending on the base used, the cream/ointment may wash off or easily absorb into the skin, or it may remain on the surface, and thus protect the skin underneath

3.6 GOOD MANUFACTURING PRACTICE

It is an essential requirement in manufacture of pharmaceuticals that the manufacturer must comply with the Code of Good Manufacturing Practice published by the Ministry of Health. Since inception, considerable efforts have been made in the manufacturing pharmaceutical industry to establish procedures and facilities that decrease the occurrence of any mishap in manufacture and packing that might adversely affect the health of the public. The Code of Good Manufacturing Practice is based on manufacturing principles established internationally, and details the standards that must be maintained by each manufacturer. Compliance with the Code is monitored by annual audit carried out by the Ministry of Health. The main points covered by the code are as follows: • The manufacturing premises must be kept clean and must be designed to allow a

product to be made in complete isolation from any other product being made at the same time.

• Equipment must be cleaned before use with all traces of the last product removed. The operator is issued with a set of batch records for each separate batch of product to be prepared.

• The batch records detail the product formula, and the manufacturing steps required to be followed in preparation of that product. The operator enters appropriate information on the batch records during manufacture, such as the identifying numbers of raw materials, the results of in-process checks etc. Once manufacture is complete, these records are retained as they constitute a complete record of the batch and must be readily accessible if required for either audit purposes or investigation of any product complaints.

Page 27: Pharma industry analysis

• Each batch of a product is given an unique identifying number which is written on the batch records and identifies the product throughout manufacture and is then used as the batch number on all labeling of product filled from the batch during packaging.

• Samples of each batch must be kept for the shelf-life of the product plus one year.

• Each raw material and finished product must comply before use or upon packaging with standards that are set down for each product. Such standards may be found in either the British Pharmacopoeia, United States Pharmacopoeia, or the European Pharmacopoeia, or may be standards that are set by the manufacturer and agreed to by appropriate regulatory authorities such as the New Zealand Ministry of Health before the product is allowed for sale. Such standards detail the tests and analytical methods which have to be performed to confirm the identity; determine the concentration of active drug; and ensure the absence of any undesirable contaminants prior to release of the product to market..

3.7 THE ROLE OF THE LABORATORY

In the pharmaceutical industry in general, the laboratory carries out three important functions: quality control; development of new, more appropriate mixtures of excipients; research into new active ingredients.

Quality control

Quality control is of crucial importance to the pharmaceutical industry, and for this reason numerous checks are made at every stage of production to ensure that quality is not compromised and that the Code of Good Manufacturing Process is adhered to. Quality control procedures include:

• Sampling of raw materials. All incoming raw materials are initially quarantined, and samples are taken and tested to ensure that the material meets strict purity guidelines. This testing involves both microbiological and chemical testing, as is laid out in the relevant Pharmacopeia (a reference book on the preparation of pharmaceuticals. Three are published - the British, United States and European Pharmacopeia).

• In-process checks. The manufacturing staff carry out checks on such things as tablet weight and size at frequent intervals. At hourly intervals the quality control staff take samples to check for contamination and to ensure that composition is as expected.

• Final product checking. Checking similar parameters to those measured during production.

• Monitoring cleaning. When a batch of a certain drug has been made, all equipment that has been used must be cleaned. When the next pharmaceutical to be made on that line is going to be different, this cleaning must be particularly thorough to prevent contamination. In this instance, after cleaning the quality control staff take swabs off each piece of equipment, and test them to see if they can detect the presence of the active previously used. Only when the equipment is so clean that the previous active is undetectable can the production of the next pharmaceutical commence

Page 28: Pharma industry analysis

3.8 Manufacturing: Cost drivers

Pharmaceutical companies can achieve year-on-year cost reduction in their overall spending by rigorously identifying and eliminating wastes in their manufacturing and business processes. Today, for many companies, Manufacturing costs, as a fraction of overall costs, is considerably higher. Therefore, it is quite logical to start with a cost reduction exercise in manufacturing.

3.8.1 Elements of cost

Pharmaceutical cost has several direct and indirect costs: Currently, pharma companies are taking a hard look at various cost elements and are coming up with various innovative ways to reduce them

Page 29: Pharma industry analysis

Cost type Cost proportion

Stratergies to optimize cost

Material cost 60-70% of Pharma manufacturing cost

• materials at a competitive landed cost, • initiatives (DMAIC) to improve batch

yields and the consumption of critical input materials.

• Process improvements to control material cost

• Improved Solvent management process • concepts of lean to eliminate wastes

Manpower cost 7-10 % • Define manning for each function based on manning norms & not on thumb rules

Energy • Ensure efficiency of energy consuming machines and preventing wastage.

• Benchmarking of key performance parameters such as efficiency, power consumption per unit production

• Timely energy audits Packing cost • reducing packing rejections and by

value-engineering the packing design • optimizing strip dimensions, number of

colors used, packing material thickness, optimal fitment of tablets within strips, number of ply, shipper sizes,

Analyzing cost (Quality cost)

• material substitution, optimizing quantities drawn for sample analysis, reduced testing, standardizing makes of chemicals across sites, clubbing samples to be cost-effective

• Enhancing equipment utilization and identifying optimum manning norms.

In addition to above following is important aspect of cost affecting manufacturing

Cost of manufacturing decision Cost of manufacturing decisions work primarily at the strategic and tactical domain, where the companies take decisions on the following:

Page 30: Pharma industry analysis

Planned versus actual capacity utilization will have an impact on product costing in terms of apportioning fixed costs over the quantity produced. Planning during the project phase ensures minimum time and cost overruns. This Reduces the cost of setting up the project. The cost of these decisions is high, and so is the impact they have in the medium to long term. Companies need to evaluate their make-buy decisions more rigorously on the back of Contribution earned. Appropriate technology selection, plant location and layout and production planning influence cost of production.

Cost reduction levers

Companies do implement manufacturing cost reduction programmes using levers such as process improvements, shared services, standardization, first principle costing, efficiency improvement, etc. Each of these levers needs to be addressed along two dimensions, strategic and operational. Decisions for strategic cost reduction will have a long- to medium-term impact. However, the complexity will be high. In operational cost reduction, the impact will be for the immediate or medium-term but relatively less complex. Many progressive companies use lean management as a concept to identify and eliminate wastes in the process, thereby resulting in additional throughput and better service levels at a lower cost. Companies have realized 10 to 15% reduction in overall costs and improvement in bottom-line savings by implementing structured cost reduction programmes.

Page 31: Pharma industry analysis

4 Pharmaceutical Supply chain

4.1 Pharmaceutical Value chain / Supply chain

• The pharmaceutical “value chain” is only partially synonymous with the

pharmaceutical “supply chain”

• The “value chain” describes how the addition of knowledge to a specific molecule

through transformational processes of R&D, pre-clinical, clinical trial, manufacture,

marketing and sales activities generates commercial value to a pharma/biotech

company

• The “supply chain” refers to the activities involved with planning, sourcing,

manufacturing and distributing your products as it does for any other company

– There is also a “clinical supply chain” which addresses sourcing and provision of

materials to clinical trail investigators

4.1.1 Pharmacy Supply Chain Considerations

The value chain of Pharmacy industry varies from other manufacturing industry primarily

due to following factors which differentiates their business needs.

• End-user (patient) safety – Anti-counterfeiting requirements – Product integrity – Quality assurance

• Fraud prevention and detection – Electronic signature requirements – Records access and retention requirements

• Product tracking – Class 2 pharmaceuticals must carry unique identifiers at the item level

Page 32: Pharma industry analysis

– “Chain of custody” tracking from manufacturer to distributors and point-of-use (“pedigree” requirements)

• End-consumers are not the principal product customers – CRM doesn’t focus on the patient (yet)

4.2 Supply chain factors The value chain of pharmacy can be attributed in the following 4 parts of operations.

1. Source 2. Make 3. Distribute 4. Buy

4.2.1 Source - Suppliers

4.2.1.1.1 Suppliers

What materials/resources do pharmaceutical suppliers provide?

• Biologic suppliers

– Chemicals

– Farm products (plants, eggs, animals, animal by-products)

– Laboratory animals

– Growth media, cell cultures

– Pathogens

– Proteins

– Test organisms

• Non-biologic suppliers

– Equipment

– Computers, software

– Databases (e.g., target molecules, DNA sequences)

– Clinical trial supplies

– Clinical trial subject population information

Single source materials Multi-source materials

• Reduced supplier management issues • Facilitates relationship-building • Risk of supply issues in the event of

– Supplier raw materials disruption – Supplier production issues – Supplier delivery issues

• Higher supplier power (Porter)

• Improved pricing and competition • Minimizes risk of supplier issues • Higher vendor management costs

Page 33: Pharma industry analysis

4.2.1.2 Supplier audit

• Foremost of all the considerations in the pharmacy supply chain – End User safety

considerations

– Are the materials provided by our suppliers safe?

– Are the products manufactured by company safe?

– Are all the products being manufactured reaching the distributors?

– Are any of our products being adulterated or counterfeited?

Thus the for supply chain of pharmacy, it’s of utmost importance to consider the End

user safety consideration to account in their operations. These considerations begin

with control of process at the source from where raw material is supplied to

organization.

Auditing of supplier to comply with the mandatory regulations of raw material supply

in accordance with consumer safety is important aspect of supplier process.

Page 34: Pharma industry analysis

• The supply chain begins with the material supplied for product manufacture

– Key ingredients need to be covered by Supply Agreements

• Price, Source, Quantity, Quality, Delivery

– Quality Agreements

• Defined Specification Control, Change Control, Complain Resolution

– Pre-purchase Usability Tests

– Toxicity Requirements

– Know where starter materials are manufactured

– Know who tests it and how

4.2.2 Make

4.2.2.1 Manufacturing Strategies for Value chain process - Components of the pharmaceutical

industry manufacturing and distribution chain

Components of the pharmaceutical industry manufacturing and distribution chain

A typical pharmaceutical supply chain will consist of the one or more of the following nodes:

(i) primary manufacturing (possibly including contractor sites); (ii) secondary manufacturing (possibly including contractor sites); (iii) market warehouses/distribution centres; (iv) wholesalers ; and (v) retailers/hospitals.

4.2.2.1.1 Primary manufacturing

The primary manufacturing site is responsible for the production of the active ingredient (AI or API). This normally involves either several chemical synthesis and separation stages to build up the complex molecules involved, or fermentation and product recovery and purification in the case of biochemical processes. The manufacturing process is characterised by

• long task processing times, often rounded to multiples of shifts. • multistage processes • considerable inventories are often held between stages.

Page 35: Pharma industry analysis

• material from an intermediate stage must often pass some form of quality control check before being approved for use downstream in the process.

• Low production volumes • Long downtime between products to avoid cross contamination of products &

requirements for validated cleaning & changeover • Low equipment utilization

Since most complex pharmaceuticals are produced through multistage processes, the same often holds true for the stable intermediates (stage products). Needless to say, this mode of operation does not lend itself well to responsiveness, and contributes significantly to some of the poor supply chain metrics exhibited by this industry. A further source of complexity (and convenience) is the use of contractors to manufacture some or indeed all of the active ingredient stages. This process of outsourcing is a growing one, as research-oriented companies concentrate on the discovery and development activities and rely on third parties’ manufacturing competence. This gives rise to extended supply chain co-ordination problems.

4.2.2.1.2 Secondary manufacturing

This is concerned with taking the active ingredient produced at the primary site and adding “excipient” inert materials along with further processing and packaging to produce the final products, usually in SKU form. For example, a product that is sold in pill form would undergo:

(i) granulation: with addition of all the excipient materials; (ii) compression: forming the pills; (iii) coating; (iv) quality control; and (v) packaging.

The secondary manufacturing locations are often geographically separate from the primary manufacturing locations. This is frequently the outcome of tax and transfer price optimization within the enterprise. There are often many more secondary manufacturing sites than primary ones, serving local or regional markets. Transportation between sites is of the order of 1 or 2 weeks if by ship (usually the default mode) and of the order of one or two days if by air. Wholesalers play a significant role in this sector. They tend to be large and few. About 80% of demand flows through this channel in the UK (with three large players accounting for almost all the demand), with the large part of the remainder going to hospitals. In the US another intermediary is growing—the managed care organization (MCO) or healthcare maintenance organization (HMO). This gives manufacturing concerns give rise to extended supply chain co-ordination problems. These are accounted by following

• Standardization of manufacturing processes

– Terminology

– Metrics

Page 36: Pharma industry analysis

– Product process “toolkits”

• Managing network assets

– Grouping plants with standard equipment and processes geared to

specific product types (e.g., dry products, freeze-dried, parenteral)

– Redundant facilities (security, shifting of work between plants)

• Improved demand forecasting

– Global demand management center

– Centralized ownership of all forecasting tools and databases

– Use of ERP web-enabled global planning capabilities

• Judicious use of contract manufacturing (e.g., packaging)

• Joint planning between product launch team and SCM team at least 1 year

before NDA submission to FDA

– Cross-functional development, marketing, clinical, SCM and regulatory teams for each product

4.2.3 Distribute

Distribution to pharmacies is different because of following

– Pharmaceutical products are dynamic (contract pricing, brand/generic,

package size)

– Product is used in a different unit of measure than acquired (unlike POS)

– Many products are interchangeable

– Product availability changes constantly

4.2.3.1 The Current Supply Chain

Three principle model of distribution

Page 37: Pharma industry analysis

• Many smaller wholesalers – partial product lines, regional players

– licensed wholesalers .

– Stock small target list of medications provided to a limited customer set

• Secondary wholesalers

– Sell to other wholesalers

– Specialize in discounted products

4.2.3.2 Continuous replenishment

Continuous replenishment of stock for distribution in pharmaceutical. Continuous

replenishment means

– Automated replenishment of pharmaceuticals driven by utilization

– Just-in-time inventory

– An end-to-end automated process for pharmaceutical procurement

Distributors are integral to this SCM concept as they perform order fulfillment

• Five core components of this SCM Concept – Site-level perpetual inventory system

– Automated inventory replenishment engine

– Store level inventory management and reporting

– Central office inventory management and reporting

– Dispensing transaction Interface (non-HIPAA)

Page 38: Pharma industry analysis

4.2.4 Buy – retailers

• Pharmacy Group Purchasing Organizations (GPOs)

– Alliances of pharmacies, hospitals and other healthcare systems

– Leverage buying power to obtain manufacturer discounts

• Often turn to secondary distribution channels when manufacturers or major

distributors cannot supply critical drugs when needed

– Drugs often stockpiled by secondary distributors for economic reasons

– Drug markups can be 500 – 1,000% during shortages

• Temperature-sensitive products, when diverted, are often not kept at the

appropriate temperatures

• Retailers attribute 48 percent of pharmaceutical inventory loss to employee theft

• Emerging requirements for secondary distributors to provide a drug pedigree that

can be tracked back to the original source (manufacturer)

– Clear “chain of custody”

– Cost of maintaining custodial information will fall on manufacturers

4.3 Supply chain

The Role of Manufacturers in the Normal Pharmaceutical Supply Chain

Manufacturers that produce prescription medicines, including brand-name, generic, and

biotech medicines, are the first link in the bio-pharmaceutical supply chain. Once these

products are manufactured, these companies sell the medicine in bulk to distributors

and wholesalers, who are then responsible for transporting medicine around the nation

and world.

Page 39: Pharma industry analysis

The Role of Distributors and Wholesalers in the Normal Pharmaceutical Supply Chain

Distributors move the bio-pharmaceutical medicines they purchase from manufacturers

to various customers, including hospitals, pharmacies and other institutions where

medications are given to patients, such as nursing homes, private physicians’ offices,

and clinics. The distribution network is made up of two components: warehouses that

stock the bio-pharmaceuticals at various distribution centers around the country and the

trucks that transport the stock where and when it is needed.

The Role of Hospitals, Clinics, and Pharmacies (Dispensers) in the Normal Pharmaceutical Supply

Chain

Hospitals, clinics and pharmacies represent the last leg on the journey from the bio-

pharmaceutical manufacturing plant to patients' medicine cabinets. Local dispensers

keep a small amount of the medicines they are likely to need on hand to meet

immediate demand. Most local pharmacies, for example, will have a certain amount of

pain medication, antibiotics, and bio-pharmaceuticals for specific conditions like heart

disease, diabetes, or asthma. When the local supplies begin to run low, the dispensing

facility will put in an order to the distributor/wholesaler (or, occasionally, directly to the

manufacturer) for more of a specific medicine.

4.3.1 Operational issues in the pharmaceutical supply chain

Although the processes will vary between companies, all major pharmaceutical companies will operate ERP systems and follow a business process along the following lines:

• Demand management—in each geographical region, forward forecasts (e.g. 3–24 months) are developed, based on historical data, market intelligence, etc. Tenders for manufacture may also be evaluated and possibly accepted at this stage.

• Inventory management and distribution requirements planning—the demands determined are aggregated and imposed on the appropriate warehouse/distribution centre. The impact on finished goods inventory is assessed and if necessary, orders are placed on upstream secondary manufacturing sites.

• Secondary production planning and scheduling—the orders placed on the secondary sites are planned (typically using MRP-II type tools) and then scheduled in detail (typically using APS tools). The impact of production plans on active ingredient raw material stocks is evaluated and if necessary, orders for AI are placed on the upstream.

• Primary manufacturing campaign planning and AI inventory management- here, the demands placed by secondary manufacturing are satisfied by careful management of inventory and production planning.

An interesting feature of this process is that the customer-facing end is effectively a “pull” process (driven by orders) but the primary manufacturing stage has long cycle times which make it difficult to ensure end-to-end responsiveness. This means that

Page 40: Pharma industry analysis

primary production is effectively a “push” process, driven by medium- and long-term forecasts. Relatively large stocks of AI must be held to ensure good service levels and ensure smooth operation at the interface of these processes. The well-documented “bullwhip” or Forrester effect is often felt at the primary manufacturing site, which is unfortunate since this is the least responsive part of the supply chain as it normally operates in campaign mode. This makes it difficult to exploit short-term opportunities (e.g. shortages of supply of a competitor’s product, tenders for national supplies, epidemics, etc.). Another feature of this process is an outcome of its large scale and geographical span. This is the distributed nature of decision-making, which can lead to ensions and sub-optimal decisions. Different nodes are not really aware of upstream nodes’ resource constraints, and orders may be filled in order of receipt, rather than on an economic basis. Of course, centralised planning would not be without its difficulties in this context. The following supply chain performance measures are typical of the industry:

Performance measure Performance value

Stock level 30-90% of annual demand quantity & 4-24 weeks of worth of finished good stock

Stock turnover (annual sales/average stock) 1-8

Supply chain cycle time(time between material entering as raw material & leaving as product )

1000-8000 hrs

Value added time (time when something happens to material as percentage of chain cycle time)

0.3 - 5%

Material efficiency (amount of product produced per unit amount of material used)

1-10%

4.3.1.1 Strategic and design issues in the pharmaceutical supply chain

• Pipeline and development management—this involves the selection of potential

drugs to develop further, and the planning of the development activity. • Process development—the investigation of manufacturing routes and the generation

of manufacturing process. • Capacity planning and plant and supply chain network design. • Plant design—the selection and sizing of the major equipment and storage units.

Some of the key issues which affect supply chain are:

• Uncertainty in the demands for existing drugs (due to competition, uncertainty in the ability to extend the protected life through new formulations, etc.).

• Uncertainty in the pipeline of new drugs—in particular, which ones will be successful in trials, what sort of dosage and treatment regime will be optimal.

Page 41: Pharma industry analysis

• Process development—this is a complex problem, driven by chemistry and yield optimisation. It often results in inefficient processes that are operated much more slowly than the intrinsic rates—giving rise to batch processes and long cycle times responsible for some of the problems seen at the primary production planning stage.

• Capacity planning—the long lead times to make capacity effective mean that decisions often need to be taken at times of high uncertainty. Waiting for the uncertainties to be resolved might delay the time to market by an unacceptable amount.

• Network design—often tax implications take precedence over logistics issues, these result in economic but potentially complicated supply chains.

• Plant design—this tends to be very traditional, with no real change in manufacturing technology for 50 years (the workhorse of the primary manufacturing site is the glass-lined stainless steel batch reactor).

Page 42: Pharma industry analysis

4.4 Supply chain: Future

Numerous forces are dictating the need for a different sort of supply chain those are

indicated in table below

To sum up, the current model for manufacturing and distributing medicines isn’t fit for Pharma’s future needs, as many industry executives recognize. The high margins that made it feasible to tie up capital in large stocks of raw materials and finished goods are ending. Most companies also have asset bases that are ill-suited to produce the sort of therapies that are now in the pipeline or to cope with new environmental regulations, so they’ll have to sell or re-engineer much of their existing plant. The change in the industry’s remit has even more fundamental implications. Pharma companies will have to manage a vast network of service providers, as well as manufacturing and distributing their own products. They will also have to acquire a much

Page 43: Pharma industry analysis

deeper understanding of patients. In a world where outcomes count for everything, it’s not molecules that create value but, rather, the ability to integrate data, products and services in a coherent business offering. Understanding this shift of emphasis from products to patient outcomes is critical; those firms that can develop and supply integrated product service packages will be able to deliver significant benefits to every stakeholder in the healthcare value chain. Many pharma companies have as a result started refining their supply chains. But most of the changes they’ve introduced have been short-term measures to address immediate challenges like the rationalization of larger manufacturing networks as a result of acquisitions. This is reflected in the progress – or, rather, lack of it – they’ve made in recent years.

4.4.1 Removing the roadblocks

Timely access to various emerging technologies will help Pharma manufacture and distribute its products more efficiently. Some of these technologies will enable it to build quality into its manufacturing processes, while others will enhance its throughput or facilitate collaboration to realize economies of scale Significant opportunities for improving the supply chain exist as below

Page 44: Pharma industry analysis

Following are the ways to improve existing supply chain

Strategy Sub strategy Benefits

New development technologies

Formulations that are easier to manufacture

• formulations that can be more easily manufactured will enable Pharma to minimize its investment in product and process development

• Development of oral biologics will eliminate the need for cold chain distribution of such therapies.

Virtual process design and validation

• computational modeling will enable Pharma to design and validate manufacturing processes virtually, using Quality by Design

• In-line process monitoring via process analytical technologies (PAT) will generate the data needed to validate these models and secure regulatory approval.

New manufacturing technologies

Flexible production • flexible processes and miniaturised, modular components that can be quickly connected or disconnected, it will be relatively easy to alter the order in which specific unit operations are performed

• These improvements will allow pharma companies to create different supply chains for different product types and markets, manage sudden shifts in demand such as the step changes associated with live licensing and reduce their manufacturing costs.

Continuous processing and automation

• Process tomography and other such technologies will enable companies to capture real-time data on critical processes, develop complex multivariate models and automatically compensate for unexpected process disturbances.

Transgenic production • Transgenic engineering offers a fundamentally different way of producing many therapeutic proteins.

• less capital expenditure, is easy to scale up or down in line with demand

Page 45: Pharma industry analysis

New distribution

technologies

• Cloud computing will provide the information platforms they need to share data securely and economically with suppliers around the world, analyze the data very rapidly and respond to sudden changes in supply and demand,

• advanced tracking technologies will enable them to monitor products from the factory gate to the patient – an increasingly important feature, as the industry manufactures more biologics with high unit values and specialist delivery requirements

New patient interface technologies

• prototype chip and receiver which records exactly when a tablet is metabolized

• interface technologies on the market and the information they generate will help patients manage their health more effectively

Greater collaboration • Greater collaboration with the other parties involved in healthcare provision will also help the industry become more efficient.

• Integrating supply chains so that all the upstream and downstream partners can see the full picture would enable them to plan ahead more accurately and manage demand more cost-effectively (indicated in table below)

Greater collaboration

Page 46: Pharma industry analysis

5 Top Growth Drivers of Pharmaceutical Industry

For the last 30 years, the pharmaceutical industry has certainly lived one of the longest and most successful business cycles as well as contributing to society. The period witnessed hundreds of new drugs approved which improved lives of millions around the world. However, many observers saw that the growth started to slow down in the late 1990’s. A confluence of several factors started to impact the comfortable business model of the patent-protected “blockbuster” approach:

• Price and reimbursement control or price increases began to be outlawed by health authorities in many markets around the world

• The R&D productivity apparently started to decline in 1996 due to a falling count of new drug approvals despite constant increase in R&D expenditures

• The industry is competing in a global market for developing and selling drugs and facing new competitors

• The centre of gravity of global wealth is shifting east with a decreasing influence by US and Europe

• The generalization process of large parts of pharma revenues from generic drugs • A pharma industry struggling with a negative image

Key important drivers of Pharmaceutical industry to sustain growth are enlisted here.

• Innovation & drug patents : especially in terms of achieving market exclusivity (against both competitors and generics competitors).If company have patents then they can come up with a unique selling proposition and isolate them self from competition. If they don't have patents they sell generic versions of drugs whose patents have expired for less than the patent holders did/do. The industry relies on a fixed period of patent protection to provide a monopoly on profits as a reward for costly R&D investment. However, the period during which these costs can be recouped has been shortened by longer time to market as a result of increased regulatory controls and barriers to market entry around price and reimbursement.

Page 47: Pharma industry analysis

historically, sales growth came both through volume and price, with peak sales at patent expiry. The decline in sales after patent expiry took years. This is indicated in picture below

Picture below indicate flatter product life cycle. Prudent purchasing by powerful Players limit initial growth and holds down prices. The expiration of the first patent in the same drug class could result in the whole class being priced as commodities, even before the patents expire. Generic substitution speeds up the sales decline

• Blockbuster model: to outset high fixed costs incurred in researching and developing new drugs and new classes of drugs.

Page 48: Pharma industry analysis

• End to end operational capabilities. Until recently pharmaceutical companies enjoyed less competition and free pricing. Without those restrictions, managers & executives developed capabilities in house, from manufacturing functions to supporting services. This environment created the bases for a “self-sufficient” organizational structure.

• Time to market - Probably the one of the most important driver in the pharmaceutical industry is the time-to-market. Companies secure very significant returns in the early life of a successful drug, before any competition. The competition-free life is shortening, typically from 5 to 1–2 years. Competition in this sense relates to similar (rather than exactly the same) drugs. It may be the case that the existence of regulatory protocols has hindered innovation in this sector; with companies blaming regulators for their own innate conservatism. The regulatory process tends to be slow and expensive; both these effects must be borne by the industry. Furthermore, the complex chemical compounds involved have more complex manufacturing processes, and the activities of route investigation, process development, scale-up plant design/retrofit, commissioning and qualification are either increasing in duration or proving stubborn to shorten. An estimate of £200–400m is required to launch a new drug, and an average of 8–12 years elapses from patent filing to first

• Development of size, sales and marketing scales. Sales scales originally to influence

prescribers and later payers. Size and marketing to industrialize their discoveries. • Global Supply : There is a general trend for companies to divest excess capacity that

came about from having many local manufacturing sites, and move towards a global supply chain management process. This brings with it many complex co-ordination issues and much tighter capacity constraints. Currently, the logistics cost in the sector is relatively high. Research efficiency is declining in the sense that the cost of each new chemical entity is increasing.

• Supply chain optimization : Historically, most management attention has been paid

to drug discovery and sales and marketing (the extreme ends of the supply chain), but now much more attention is being paid to supply chain optimization as a means of delivering value.

According to Booth (1999): • there is a welcome move away from viewing the supply chain as merely

having to deliver security of supply at minimum cost, to a recognition of its ability to generate both value for the customer and hence to the shareholder;

• restructuring of the supply chain along regional and global lines will require massive reductions in capacity, which was acquired in many cases to propitiate national interest in return for sympathetic pricing.

Page 49: Pharma industry analysis

• Embracing Change in organizations - We believe that element for fueling growth is the way pharmaceutical companies will embrace change within their organizations. A shift in mind set hence in behaviors is needed in order to redefine success. Commonly, change is lead from the top. However, too often the change required does not permeate the whole organization. Top management has its own “customer”, generally the shareholder. To satisfy shareholders often means to give a certain ROI which often conflicts with innovation, with doing things differently. Hence, people further down the organization don’t dare to innovate. There is a “resigned behavioral compliance” which stifles changes. Who is to blame? Who wants to swim against the tide? Leaders should change their minds and behave coherently to show the way to change for the rest of their organizations or to let parts of the organization to try changes. As an example, I remember delivering a workshop in a seminar for a large pharmaceutical company on the topic of innovation. The participating Senior Managers from different affiliates complained that they were asked to make innovative business proposals which almost every time were finally rejected on the ground that no short term ROI would be demonstrated. Trying to create competitive advantage, daring to propose and implement stepwise new ways of working, of competing should be part of a firm’s DNA. Pharmaceutical companies are very conservative and the command and control is still the way forward whereas cross functional teamwork, people engagements on innovative ways at looking the business should be the norm.

• Companies should also explore and exploit R&D from different perspectives and we

gave the example of revisiting dormant compounds. For personalized medicines, the challenges are the development costs, the regulatory and reimbursement conditions and the involvement of other stakeholders like the patient, the insurer. This business model is costly and the risk is that it may turn out as short lived if the society is not ready to pay for it.

• Companies should be active in creating alliances with non-pharma industry partners. Because those companies may represent new entrants who will become strong game-changers in the near future.

Apart from above drivers following forces that are also likely to have a high impact on the industry:

a) Increasing concentration of buyers b) Increasing power of distributors (parallel trade) c) Generic substitutes d) Scientific advances leading to new drug discovery processes and greater targeting of treatments e) Government pressure on costs and intervention f) Harmonious healthcare practice

Page 50: Pharma industry analysis

6 Challenges for Pharmaceutical Industry

6.1 Changing trends & Implications

Summary of key trends in pharmaceutical industry & their implications in table below

Page 51: Pharma industry analysis

6.2 Manufacturing challenges

Page 52: Pharma industry analysis

6.3 Supply chain challenges

Page 53: Pharma industry analysis

6.4 Other Challenges for Pharmaceutical industry in India

• Infrastructure - Insufficient energy infrastructure and inadequate transport infrastructure has historically posed challenges for companies operating in India.

• Counterfeit - Counterfeit drugs have been a serious issue in India. • Intellectual Property rights _ Intellectual property rights act in India does not allow any

protection for patents before 1995. The ordinance also allows opposition for the

application of patent thereby further delaying the grant process.

Page 54: Pharma industry analysis

7 References

• PWC (2012) research ,”Pharma 2020 : Supplying future”

• PWC (2012) research ,”Global Pharma Looks to India : Prospects for Growth”

• Evaluate Pharma, “World Preview 2016” (May 2010).

• Rajesh Yadav & Naveen Yadav,”Pharmaceutical Processing – A Review on Wet

Granulation Technology “ Journal (April -June 2011)

http://www.ijpfr.com/Dacuments/2011/7.pdf

• http://pharmabiz.com/NewsDetails.aspx?aid=69318&sid=1 (June 2012)

• http://www.mckinsey.com/locations/india/mckinseyonindia/pdf/India_Pharma_2015.pdf

Page 55: Pharma industry analysis

Appendix

Current & future market for Indian Pharma :

Page 56: Pharma industry analysis

Indian Pharma : Advantages

Fundamentals of Growth for Indian Pharma

Page 57: Pharma industry analysis